These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33324229)

  • 1. Corrigendum: Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.
    Bartmann L; Schumacher D; von Stillfried S; Sternkopf M; Alampour-Rajabi S; van Zandvoort MAMJ; Kiessling F; Wu Z
    Front Pharmacol; 2020; 11():617329. PubMed ID: 33324229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.
    Bartmann L; Schumacher D; von Stillfried S; Sternkopf M; Alampour-Rajabi S; van Zandvoort MAMJ; Kiessling F; Wu Z
    Front Pharmacol; 2019; 10():79. PubMed ID: 30787877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riboflavin-Targeted Drug Delivery.
    Darguzyte M; Drude N; Lammers T; Kiessling F
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional (intestinal-specific) knockout of the riboflavin transporter-3 (RFVT-3) impairs riboflavin absorption.
    Subramanian VS; Lambrecht N; Lytle C; Said HM
    Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(4):G285-93. PubMed ID: 26660539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy.
    Zhou Y; Gao X; Yuan M; Yang B; He Q; Cao J
    Front Pharmacol; 2021; 12():785732. PubMed ID: 34744754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52.
    Yonezawa A; Inui K
    Mol Aspects Med; 2013; 34(2-3):693-701. PubMed ID: 23506902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy.
    Bhagwat GS; Athawale RB; Gude RP; Md S; Alhakamy NA; Fahmy UA; Kesharwani P
    Front Pharmacol; 2022; 13():1123542. PubMed ID: 36712681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes.
    Arjmand B; Kokabi Hamidpour S; Alavi-Moghadam S; Yavari H; Shahbazbadr A; Rezaei-Tavirani M; Gilany K; Larijani B
    Front Pharmacol; 2022; 13():892656. PubMed ID: 35586055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum: Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of
    Ilic M; Maier J; Holy M; Jaentsch K; Liechti ME; Lubec G; Baumann MH; Sitte HH; Luethi D
    Front Pharmacol; 2022; 13():878641. PubMed ID: 35370673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery.
    Liu X; Wu L; Wang L; Jiang W
    Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum: Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature [Corrigendum].
    Int J Nanomedicine; 2022; 17():183-184. PubMed ID: 35046653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Editorial: Serotonin and Memory.
    Meneses A; Gasbarri A
    Front Pharmacol; 2016; 7():36. PubMed ID: 26903871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: Sesquiterpene lactones attenuate paclitaxel resistance via inhibiting MALAT1/STAT3/ FUT4 axis and P-Glycoprotein transporters in lung cancer cells.
    Ding Y; Zhen Z; Nisar MA; Ali F; Din RU; Khan M; Mughal TA; Alam G; Liu L; Saleem MZ
    Front Pharmacol; 2024; 15():1363218. PubMed ID: 38698815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: Theranostic Nanomedicine for Malignant Gliomas.
    d'Angelo M; Castelli V; Benedetti E; Antonosante A; Catanesi M; Dominguez-Benot R; Pitari G; Ippoliti R; Cimini A
    Front Bioeng Biotechnol; 2019; 7():468. PubMed ID: 32083065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Paraptosis: a unique cell death mode for targeting cancer.
    Hanson S; Dharan A; V JP; Pal S; Nair BG; Kar R; Mishra N
    Front Pharmacol; 2023; 14():1274076. PubMed ID: 37745056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets.
    Brandão-Teles C; de Almeida V; Cassoli JS; Martins-de-Souza D
    Front Pharmacol; 2019; 10():344. PubMed ID: 31024311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases.
    Cavalli G; Dinarello CA
    Front Pharmacol; 2019; 10():148. PubMed ID: 30906259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.
    Crocker CE; Tibbo PG
    Front Pharmacol; 2018; 9():1417. PubMed ID: 30555331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital.
    Khan Z; Karataş Y; Kıroğlu O
    Front Pharmacol; 2021; 12():813892. PubMed ID: 35095527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: Targeting Anion Exchange of Osteoclast, a New Strategy for Preventing Wear Particles Induced-Osteolysis.
    Wu C; Liu X; Sun R; Qin Y; Liu Z; Yang S; Tang T; Zhu Z; Yu D; Liu F
    Front Pharmacol; 2019; 10():1078. PubMed ID: 31588207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.